|
|
Prepublished online as a Blood First Edition Paper on June 7, 2002; DOI 10.1182/blood-2002-01-0159.
 Previous Article | Table of Contents | Next Article 
Blood, 1 August 2002, Vol. 100, No. 3, pp. 768-773
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Phase II trial of subcutaneous anti-CD52 monoclonal antibody
alemtuzumab (Campath-1H) as first-line treatment for patients with
B-cell chronic lymphocytic leukemia (B-CLL)
Jeanette Lundin,
Eva Kimby,
Magnus Björkholm,
Per-Anders Broliden,
Fredrik Celsing,
Viktoria Hjalmar,
Lars Möllgård,
Peppy Rebello,
Geoff Hale,
Herman Waldmann,
Håkan Mellstedt, and
Anders Österborg
From the Departments of Hematology and Oncology,
Karolinska Hospital, and Huddinge University Hospital, Stockholm,
Sweden; and Therapeutic Antibody Center, Oxford, United Kingdom.
This phase II study determined the efficacy and safety of
alemtuzumab, a humanized anti-CD52 monoclonal antibody, delivered subcutaneously as first-line therapy, over a prolonged treatment period
of 18 weeks in 41 patients with symptomatic B-cell chronic lymphocytic
leukemia (B-CLL). Injections were administered subcutaneously 3 times
per week, from week 2 to 3 onward. An overall response rate (OR) of
87% (95% CI, 76%-98%; complete remission [CR], 19%; partial
remission [PR], 68%) was achieved in 38 evaluable patients (81% of
intent-to-treat population). CLL cells were cleared from blood in 95%
patients in a median time of 21 days. CR or nodular PR in the bone
marrow was achieved in 66% of the patients and most patients achieved
this after 18 weeks of treatment. An 87% OR (29% CR) was achieved in
the lymph nodes. The median time to treatment failure has not yet been
reached (18+ months; range, 8-44+ months). Transient injection site
skin reactions were seen in 90% of patients. Rigor, rash, nausea,
dyspnea, and hypotension were rare or absent. Transient grade IV
neutropenia developed in 21% of the patients. Infections were rare,
but 10% patients developed cytomegalovirus (CMV) reactivation. These
patients rapidly responded to intravenous ganciclovir. One patient,
allergic to cotrimoxazole prophylaxis, developed
Pneumocystis carinii pneumonia. Alemtuzumab is
highly effective as first-line treatment in patients with B-CLL.
Prolonged treatment is important for maximal bone marrow response.
Subcutaneous administration induced very few "first-dose" flulike
symptoms and may reduce health care costs in comparison with the
intravenous infusions.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Elter, J. Kilp, P. Borchmann, H. Schulz, M. Hallek, and A. Engert
Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
Haematologica,
January 1, 2009;
94(1):
150 - 152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O'Brien, F. Ravandi, T. Riehl, W. Wierda, X. Huang, J. Tarrand, B. O'Neal, H. Kantarjian, and M. Keating
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy
Blood,
February 15, 2008;
111(4):
1816 - 1819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda
Treatments for Patients with Chronic Lymphocytic Leukemia
ASCO Educational Book,
January 1, 2008;
2008(1):
297 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hillmen, A. B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, and J. Mayer
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
December 10, 2007;
25(35):
5616 - 5623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Dearden
Role of antibody therapy in lymphoid malignancies
Br. Med. Bull.,
September 1, 2007;
83(1):
275 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tang, J. Lou, R. K. Alpaugh, M. K. Robinson, J. D. Marks, and L. M. Weiner
Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen
J. Immunol.,
September 1, 2007;
179(5):
2815 - 2823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. DeNardo, A. Natarajan, S. Hok, J. Perkins, M. Cosman, S. J. DeNardo, F. C. Lightstone, G. R. Mirick, L. A. Miers, and R. L. Balhorn
Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma
J. Nucl. Med.,
August 1, 2007;
48(8):
1338 - 1347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Marie, S. Robaday, J.M. Kerleau, F. Jardin, and H. Levesque
Typhlitis as a complication of alemtuzumab therapy
Haematologica,
May 1, 2007;
92(5):
e62 - e63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kolstad, H. Holte, A. Fossa, G. F. Lauritzsen, P. Gaustad, and D. Torfoss
Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen
Haematologica,
January 1, 2007;
92(1):
139 - 140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Morrison
Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia
Hematology,
January 1, 2007;
2007(1):
332 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Williams, J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor
Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia
J. Immunol.,
November 15, 2006;
177(10):
7435 - 7443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sandherr, H. Einsele, H. Hebart, C. Kahl, W. Kern, M. Kiehl, G. Massenkeil, O. Penack, X. Schiel, S. Schuettrumpf, et al.
Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)
Ann. Onc.,
July 1, 2006;
17(7):
1051 - 1059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Montillo, A. Tedeschi, S. Miqueleiz, S. Veronese, R. Cairoli, L. Intropido, F. Ricci, A. Colosimo, B. Scarpati, M. Montagna, et al.
Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 20, 2006;
24(15):
2337 - 2342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch
How I treat refractory CLL
Blood,
February 15, 2006;
107(4):
1276 - 1283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda
Current and Investigational Therapies for Patients with CLL
Hematology,
January 1, 2006;
2006(1):
285 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lundin, F. Celsing, C. Karlsson, and A. Osterborg
Treatment of Refractory Autoimmune Hemolytic Anemia in B-CLL with Alemtuzumab (Humanized CD52 MAb).
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
2967 - 2967.
[Abstract]
|
|
|
|
|
|
|
M. R. Rezvany, M. J. Tehrani, C. Karlsson, J. Lundin, H. Rabbani, H. Mellstedt, and A. Osterborg
Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL).
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
2986 - 2986.
[Abstract]
|
|
|
|
|
|
|
A. Mone, S. Puhalla, S. Whitman, R. A. Baiocchi, J. Cruz, T. Vukosavljevic, A. Banks, C. F. Eisenbeis, J. C. Byrd, M. A. Caligiuri, et al.
Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia
Blood,
November 15, 2005;
106(10):
3380 - 3382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Wang, L. Martensson, R. Nilsson, P.-O. Bendahl, L. Lindgren, T. Ohlsson, H.-O. Sjogren, S.-E. Strand, and J. Tennvall
Blood Pharmacokinetics of Various Monoclonal Antibodies Labeled with a New Trifunctional Chelating Reagent for Simultaneous Conjugation with 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid and Biotin before Radiolabeling
Clin. Cancer Res.,
October 1, 2005;
11(19):
7171s - 7177s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. M. van Leeuwen, G. J. de Bree, E. B. M. Remmerswaal, S.-L. Yong, K. Tesselaar, I. J. M. t. Berge, and R. A. W. van Lier
IL-7 receptor {alpha} chain expression distinguishes functional subsets of virus-specific human CD8+ T cells
Blood,
September 15, 2005;
106(6):
2091 - 2098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda, T. J. Kipps, and M. J. Keating
Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
September 10, 2005;
23(26):
6325 - 6332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P Levene, G. Singh, and C. Palmieri
Therapeutic monoclonal antibodies in oncology
J R Soc Med,
April 1, 2005;
98(4):
146 - 152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Lin, I. W. Flinn, R. Modali, T. A. Lehman, J. Webb, S. Waymer, M. E. Moran, M. S. Lucas, S. S. Farag, and J. C. Byrd
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
Blood,
January 1, 2005;
105(1):
289 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Milligan, S. Fernandes, R. Dasgupta, F. E. Davies, E. Matutes, C. D. Fegan, C. McConkey, J. A. Child, D. Cunningham, G. J. Morgan, et al.
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses
Blood,
January 1, 2005;
105(1):
397 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Shahied, Y. Tang, R. K. Alpaugh, R. Somer, D. Greenspon, and L. M. Weiner
Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format
J. Biol. Chem.,
December 24, 2004;
279(52):
53907 - 53914.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hale, P. Rebello, L. R. Brettman, C. Fegan, B. Kennedy, E. Kimby, M. Leach, J. Lundin, H. Mellstedt, P. Moreton, et al.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Blood,
August 15, 2004;
104(4):
948 - 955.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Enblad, H. Hagberg, M. Erlanson, J. Lundin, A. P. MacDonald, R. Repp, J. Schetelig, G. Seipelt, and A. Osterborg
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
Blood,
April 15, 2004;
103(8):
2920 - 2924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Basquiera, A. R. Berretta, J. J. Garcia, and E. D. Palazzo
Coronary ischemia related to alemtuzumab therapy
Ann. Onc.,
March 1, 2004;
15(3):
539 - 540.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hakki, S. R. Riddell, J. Storek, R. A. Carter, T. Stevens-Ayers, P. Sudour, K. White, L. Corey, and M. Boeckh
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
Blood,
October 15, 2003;
102(8):
3060 - 3067.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. M. Mackus, F. N. J. Frakking, A. Grummels, L. E. Gamadia, G. J. de Bree, D. Hamann, R. A. W. van Lier, and M. H. J. van Oers
Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia
Blood,
August 1, 2003;
102(3):
1057 - 1063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lundin, H. Hagberg, R. Repp, E. Cavallin-Stahl, S. Freden, G. Juliusson, E. Rosenblad, G. Tjonnfjord, T. Wiklund, and A. Osterborg
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
Blood,
June 1, 2003;
101(11):
4267 - 4272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mavromatis and B. D. Cheson
Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 1, 2003;
21(9):
1874 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, D. A. Thomas, S. O'Brien, G. Garcia-Manero, H. M. Kantarjian, F. J. Giles, C. Koller, A. Ferrajoli, S. Verstovsek, B. Pro, et al.
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
Blood,
May 1, 2003;
101(9):
3413 - 3415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps
Biology and Treatment of Chronic Lymphocytic Leukemia
Hematology,
January 1, 2003;
2003(1):
153 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. N. O'Brien, N. M.A. Blijlevens, T. H. Mahfouz, and E. J. Anaissie
Infections in Patients with Hematological Cancer: Recent Developments
Hematology,
January 1, 2003;
2003(1):
438 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
